{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:51:17Z","timestamp":1787028677247,"version":"build-2736575974"},"reference-count":55,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Antiplatelet medications such as aspirin and clopidogrel are used following thrombotic stroke or transient ischemic attack (TIA) to prevent a recurrent stroke. However, the antiplatelet treatments fail frequently, and patients experience recurrent stroke. One approach to lower the rates of recurrence may be the individualized antiplatelet therapies (antiplatelet therapy modification (ATM)) based on the results of platelet function analysis (PFA). This review was undertaken to gather and analyze the evidence about the effectiveness of such approaches. Methods: We searched Medline, CINAHL, Embase, Web of Science, and Cochrane databases up to 7 January 2020. Results: Two observational studies involving 1136 patients were included. The overall effects of PFA-based ATM on recurrent strokes (odds ratio (OR) 1.05; 95% confidence interval (CI) 0.69 to 1.58), any bleeding risk (OR 1.39; 95% CI 0.92 to 2.10) or death hazard from any cause (OR 1.19; 95% CI 0.62 to 2.29) were not significantly different from the standard antiplatelet therapy without ATM. Conclusions: The two studies showed opposite effects of PFA-guided ATM on the recurrent strokes in aspirin non-responders, leading to an insignificant difference in the subgroup meta-analysis (OR 1.59; 95% CI 0.07 to 33.77), while the rates of any bleeding events (OR 1.04; 95% CI 0.49 to 2.17) or death from any cause (OR 1.17; 95% CI 0.41 to 3.35) were not significantly different between aspirin non-responders with ATM and those without ATM. There is a need for large, randomized controlled trials which account for potential confounders such as ischemic stroke subtypes, technical variations in the testing protocols, patient adherence to therapy and pharmacogenetic differences.<\/jats:p>","DOI":"10.3390\/jcm9123907","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T20:06:09Z","timestamp":1606853169000},"page":"3907","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effectiveness of Platelet Function Analysis-Guided Aspirin and\/or Clopidogrel Therapy in Preventing Secondary Stroke: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2286-7943","authenticated-orcid":false,"given":"Ann-Rong","family":"Yan","sequence":"first","affiliation":[{"name":"School of Health Sciences, Faculty of Health, University of Canberra, Canberra 2617, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6422-7170","authenticated-orcid":false,"given":"Mark","family":"Naunton","sequence":"additional","affiliation":[{"name":"School of Health Sciences, Faculty of Health, University of Canberra, Canberra 2617, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6764-3882","authenticated-orcid":false,"given":"Gregory M.","family":"Peterson","sequence":"additional","affiliation":[{"name":"School of Health Sciences, Faculty of Health, University of Canberra, Canberra 2617, Australia"},{"name":"School of Pharmacy and Pharmacology, University of Tasmania, Hobart 7000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Fernandez-Cadenas","sequence":"additional","affiliation":[{"name":"Stroke Pharmacogenomics and Genetics Group, Neurovascular Research Laboratory, Hospital de Sant Pau, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8885-0891","authenticated-orcid":false,"given":"Reza","family":"Mortazavi","sequence":"additional","affiliation":[{"name":"School of Health Sciences, Faculty of Health, University of Canberra, Canberra 2617, Australia"},{"name":"Prehab Activity Cancer Exercise Survivorship Research Group, Faculty of Health, University of Canberra, Canberra 2617, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,1]]},"reference":[{"key":"ref_1","unstructured":"Australian Institute of Health and Welfare (2013). Stroke and Its Management in Australia: An Update, Australian Institute of Health and Welfare."},{"key":"ref_2","first-page":"437","article-title":"Secondary stroke prevention: Challenges and solutions","volume":"11","author":"Esenwa","year":"2015","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ane.13093","article-title":"Recurrent ischemic stroke: Incidence, predictors, and impact on mortality","volume":"140","author":"Khanevski","year":"2019","journal-title":"Acta Neurol. Scand."},{"key":"ref_5","unstructured":"Stroke Foundation (2020, April 12). Clinical Guidelines for Stroke Management 2017. Available online: https:\/\/informme.org.au\/Guidelines\/Clinical-Guidelines-for-Stroke-Management-2017."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Ildstad, F., Ellekj\u00e6r, H., Wethal, T., Lydersen, S., Sund, J.K., Fj\u00e6rtoft, H., Sch\u00fcler, S., Horn, J.W., Br\u00e5then, G., and Midts\u00e6ther, A.G. (2019). Stroke risk after transient ischemic attack in a Norwegian prospective cohort. BMC Neurol., 19.","DOI":"10.1186\/s12883-018-1225-y"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1161\/01.STR.0000080935.01264.91","article-title":"Very Early Risk of Stroke After a First Transient Ischemic Attack","volume":"34","author":"Lovett","year":"2003","journal-title":"Stroke"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.pharmthera.2015.06.004","article-title":"Pharmacological therapy of acute ischaemic stroke: Achievements and problems","volume":"153","author":"Moretti","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1160\/TH17-07-0492","article-title":"Atherothrombosis and thromboembolism: Position paper from the second maastricht consensus conference on thrombosis","volume":"118","author":"Spronk","year":"2018","journal-title":"Thromb. Haemost."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100583","DOI":"10.1016\/j.blre.2019.05.007","article-title":"Platelet activation markers in evaluation of thrombotic risk factors in various clinical settings","volume":"37","author":"Kannan","year":"2019","journal-title":"Blood Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/VHRM.S44469","article-title":"Platelet function tests: A comparative review","volume":"11","author":"Paniccia","year":"2015","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"m713","DOI":"10.1182\/blood-2017-03-742338","article-title":"How i use laboratory monitoring of antiplatelet therapy","volume":"130","author":"Michelson","year":"2017","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3109\/09537104.2015.1049139","article-title":"Platelet function testing in transient ischaemic attack and ischaemic stroke: A comprehensive systematic review of the literature","volume":"26","author":"Lim","year":"2015","journal-title":"Platelets"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(06)68040-9","article-title":"Aspirin resistance","volume":"367","author":"Hankey","year":"2006","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1515\/jccm-2015-0021","article-title":"Anti-platelet Therapy Resistance\u2014Concept, Mechanisms and Platelet Function Tests in Intensive Care Facilities","volume":"2","author":"Marginean","year":"2016","journal-title":"J. Crit. Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/jcph.769","article-title":"The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway","volume":"56","author":"Ford","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/ncpcardio0602","article-title":"Drug Insight: Clopidogrel nonresponsiveness","volume":"3","author":"Gurbel","year":"2006","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1586\/ern.10.203","article-title":"Antiplatelet resistance in stroke","volume":"11","author":"Topcuoglu","year":"2011","journal-title":"Expert Rev. Neurother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jns.2017.03.010","article-title":"High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: A systematic review and meta-analysis","volume":"376","author":"Fiolaki","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12883-016-0778-x","article-title":"Assessment of platelet function in patients with stroke using multiple electrode platelet aggregometry: A prospective observational study","volume":"16","author":"Sabra","year":"2016","journal-title":"BMC Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00415-003-0954-y","article-title":"Aspirin non-responder status in patients with recurrent cerebral ischemic attacks","volume":"250","author":"Grundmann","year":"2003","journal-title":"J. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/0091270007313324","article-title":"Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events","volume":"48","author":"Gengo","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1212\/WNL.0000000000002657","article-title":"Aspirin resistance is associated with increased stroke severity and infarct volume","volume":"86","author":"Oh","year":"2016","journal-title":"Neurology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1001\/jamaneurol.2013.601","article-title":"Association of Aspirin Resistance with Increased Stroke Severity and Infarct Size","volume":"70","author":"Zheng","year":"2013","journal-title":"JAMA Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1007\/s00415-011-6052-7","article-title":"Aspirin resistance in patients with acute ischemic stroke","volume":"258","author":"Ozben","year":"2011","journal-title":"J. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000438722","article-title":"Interest of Antiplatelet Drug Testing after an Acute Ischemic Stroke","volume":"74","author":"Coignion","year":"2015","journal-title":"Eur. Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1007\/s00415-016-8181-5","article-title":"Antiplatelet drug resistance is associated with early neurological deterioration in acute minor ischemic stroke in the Chinese population","volume":"263","author":"Yi","year":"2016","journal-title":"J. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.02.013","article-title":"Clopidogrel Resistance Increases Rate of Recurrent Stroke and Other Vascular Events in Chinese Population","volume":"25","author":"Yi","year":"2016","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000315147","article-title":"Biochemical Aspirin Resistance and Recurrent Lesions in Patients with Acute Ischemic Stroke","volume":"64","author":"Jeon","year":"2010","journal-title":"Eur. Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.brainresbull.2018.07.004","article-title":"Aspirin resistance predicts unfavorable functional outcome in acute ischemic stroke patients","volume":"142","author":"Wang","year":"2018","journal-title":"Brain Res. Bull."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.04.012","article-title":"High On-Treatment Platelet Reactivity to Adenosine Diphosphate Predicts Ischemic Events of Minor Stroke and Transient Ischemic Attack","volume":"26","author":"Rao","year":"2017","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/01616412.2017.1312793","article-title":"The association between high on-treatment platelet reactivity and early recurrence of ischemic events after minor stroke or TIA","volume":"39","author":"Rao","year":"2017","journal-title":"Neurol. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/194927b0","article-title":"Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal","volume":"194","author":"Born","year":"1962","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.blre.2004.05.002","article-title":"Platelet function analysis","volume":"19","author":"Harrison","year":"2005","journal-title":"Blood Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jacc.2007.12.044","article-title":"Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study","volume":"51","author":"Bonello","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1160\/TH15-11-0870","article-title":"Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. A review of the literature","volume":"116","author":"Negrier","year":"2016","journal-title":"Thromb. Haemost."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1161\/STROKEAHA.110.593582","article-title":"The use of platelet function assays may help to determine appropriate antiplatelet treatment options in a patient with recurrent stroke on baby aspirin: Against","volume":"41","author":"Eikelboom","year":"2010","journal-title":"Stroke"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1160\/TH12-08-0608","article-title":"Evaluating the clinical usefulness of platelet function testing: Considerations for the proper application and interpretation of performance measures","volume":"109","author":"Dahlen","year":"2013","journal-title":"Thromb. Haemost."},{"key":"ref_39","unstructured":"Wells, G.A., Shea, B., O\u2019Connell, D., Peterson, J., Welch, V., Losos, M., and Tugwell, P. (2020, April 12). The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Available online: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1161\/STROKEAHA.112.655084","article-title":"Clinical Outcomes Using a Platelet Function-Guided Approach for Secondary Prevention in Patients With Ischemic Stroke or Transient Ischemic Attack","volume":"43","author":"Depta","year":"2012","journal-title":"Stroke"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"106258","DOI":"10.18632\/oncotarget.22293","article-title":"Platelet function-guided modification in antiplatelet therapy after acute ischemic stroke is associated with clinical outcomes in patients with aspirin nonresponse","volume":"8","author":"Yi","year":"2017","journal-title":"Oncotarget"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.10.015","article-title":"Pathophysiologic, Rather than Laboratory-defined Resistance Drives Aspirin Failure in Ischemic Stroke","volume":"24","author":"Agayeva","year":"2015","journal-title":"J Stroke Cereb. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s11239-013-0919-7","article-title":"Effectiveness of antiplatelet therapy in atherosclerotic disease: Comparing the ASA low-response prevalence in CVD, CAD and PAD","volume":"37","author":"Meves","year":"2014","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","article-title":"Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment","volume":"24","author":"Adams","year":"1993","journal-title":"Stroke"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"824","DOI":"10.2174\/157016111106140128113705","article-title":"Stroke subtypes and their possible implication in stroke prevention drug strategies","volume":"11","author":"Tuttolomondo","year":"2013","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11239-015-1304-5","article-title":"High residual platelet reactivity (HRPR) for adenosine diphosphate (ADP) stimuli is a determinant factor for long-term outcomes in acute ischemic stroke with anti-platelet agents: The meaning of HRPR after ADP might be more prominent in large atherosclerotic infarction than other subtypes of AIS","volume":"42","author":"Cha","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jns.2008.10.013","article-title":"Aspirin resistance in South African Caucasian patients with thrombotic cerebrovascular events","volume":"277","author":"Bernstein","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1755-5922.2010.00188.x","article-title":"Aspirin Resistance and Compliance with Therapy","volume":"29","author":"Dawson","year":"2011","journal-title":"Cardiovasc. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1160\/TH11-01-0045","article-title":"Aspirin failure in patients presenting with acute cerebrovascular ischaemia","volume":"106","author":"Halawani","year":"2011","journal-title":"Thromb. Haemost."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.clineuro.2012.09.025","article-title":"Clinical and biochemical aspirin resistance in patients with recurrent cerebral ischemia","volume":"115","author":"Azzam","year":"2013","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1600-0404.2005.00419.x","article-title":"Aspirin resistance in secondary stroke prevention","volume":"113","author":"Berrouschot","year":"2006","journal-title":"Acta Neurol. Scand."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e008313","DOI":"10.1161\/JAHA.117.008313","article-title":"Clinical significance of acute and serial platelet function testing in acute ischemic stroke","volume":"7","author":"Kim","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000090357","article-title":"New modalities and aspects of antiplatelet therapy for stroke prevention","volume":"21","author":"Uchiyama","year":"2006","journal-title":"Cerebrovasc. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1468-1331.2009.02837.x","article-title":"Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: A double-blind randomized clinical trial","volume":"17","author":"Lee","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.05.031","article-title":"\u201cAspirin Resistance\u201d in Ischemic Stroke: Insights Using Short Thrombelastography","volume":"22","author":"Sambu","year":"2013","journal-title":"J. Stroke Cerebrovasc. Dis."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/12\/3907\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:40:17Z","timestamp":1760179217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/12\/3907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":55,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["jcm9123907"],"URL":"https:\/\/doi.org\/10.3390\/jcm9123907","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202011.0334.v1","asserted-by":"object"}]},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,1]]}}}